Related Experiment Video
Updated: Jul 9, 2025
Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies
Published on: January 31, 2025
Plasma proteomic profiles predict individual future health risk
1Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, Institute of Science and Technology for Brain-Inspired Intelligence, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Fudan University, Shanghai, China.
A new proteomic risk score (ProRS) identifies individuals at high risk for 45 diseases and mortality. This blood-based score shows high accuracy, outperforming current clinical indicators for predicting future health events.
Area of Science:
- Proteomics
- Biomarker Discovery
- Preventive Medicine
Background:
- Identifying individuals at high risk for future diseases and mortality is crucial for preventive medicine.
- Current risk assessment tools often focus on single diseases and may not capture comprehensive individual risk.
Purpose of the Study:
- To develop and validate a single, integrated proteomic risk score (ProRS) for predicting a wide range of diseases and mortality.
- To assess the performance of ProRS compared to established clinical indicators.
Main Methods:
- A neural network was trained using Olink proteomic data from 52,006 UK Biobank participants.
- The study analyzed 1461 plasma proteins to create the ProRS.
- Performance was evaluated for 45 common conditions, including various diseases, cancers, and mortality.
Main Results:
- The ProRS significantly stratified risk across 45 diverse health conditions.
- High predictive accuracy (C-indexes >0.80) was observed for endpoints like cancer, dementia, and death.
- ProRS demonstrated superior or equivalent predictive performance compared to existing clinical indicators.
Conclusions:
- Proteomic profiles, as captured by ProRS, offer a powerful tool for comprehensive, multi-disease risk assessment.
- ProRS shows potential to replace or augment complex laboratory tests and clinical measures for improved risk prediction.
- Further external validation is required before clinical implementation.
